Made into a permanent programme in 2009, it set out to sequence the genomes of potential bioterror agents, explore new drug technologies and develop «broad - spectrum» therapies that would work against multiple bacterial and viral pathogens —
especially haemorrhagic fever viruses such as Ebola and Marburg.